NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free INM Stock Alerts $0.29 +0.01 (+3.51%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.27▼$0.3350-Day Range$0.23▼$0.3852-Week Range$0.23▼$2.08Volume2.30 million shsAverage Volume388,581 shsMarket Capitalization$1.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get InMed Pharmaceuticals alerts: Email Address InMed Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.06Based on 2 Articles This WeekInsider TradingAcquiring Shares$29,601 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.19 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for InMed Pharmaceuticals.Read more about InMed Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.92% of the outstanding shares of InMed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently increased by 213.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INM. Previous Next 1.7 News and Social Media Coverage News SentimentInMed Pharmaceuticals has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InMed Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for INM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,601.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.39% of the stock of InMed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 20.12% of the stock of InMed Pharmaceuticals is held by institutions.Read more about InMed Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioInMed Pharmaceuticals has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about InMed Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About InMed Pharmaceuticals Stock (NASDAQ:INM)InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More INM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INM Stock News HeadlinesMay 18 at 3:20 AM | americanbankingnews.comInMed Pharmaceuticals (NASDAQ:INM) Shares Up 3.5%April 17, 2024 | theglobeandmail.comInMed (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMDMarch 23, 2024 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day ExtensionFebruary 10, 2024 | markets.businessinsider.comInMed Pharmaceuticals Welcomes New CFO Neeta JagpalFebruary 10, 2024 | msn.comInMed Pharmaceuticals Announces New CFO AppointmentFebruary 9, 2024 | finance.yahoo.comInMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial OfficerJanuary 25, 2024 | benzinga.comInMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet NeedJanuary 18, 2024 | finance.yahoo.comInMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ETDecember 20, 2023 | finanznachrichten.deInMed Pharmaceuticals: InMed Announces Results of 2023 Annual General MeetingDecember 19, 2023 | finance.yahoo.comInMed Announces Results of 2023 Annual General MeetingNovember 14, 2023 | finance.yahoo.comInMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business UpdateNovember 8, 2023 | msn.comInMed Pharmaceuticals files to sell 12.57M shares for holdersNovember 8, 2023 | morningstar.comInMed Pharmaceuticals Inc INMNovember 2, 2023 | finance.yahoo.comInMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023October 27, 2023 | finance.yahoo.comInMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq RulesOctober 25, 2023 | investorplace.comWhy Is InMed Pharmaceuticals (INM) Stock Down 25% Today?October 24, 2023 | msn.comInMed Pharmaceuticals to raise $5.2M via private placementOctober 24, 2023 | finance.yahoo.comInMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq RulesOctober 24, 2023 | benzinga.comDow Surges 250 Points; US Manufacturing PMI Tops ExpectationsOctober 24, 2023 | benzinga.comWhy InMed Pharmaceuticals Stock Is Soaring TuesdayOctober 3, 2023 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Releases FY 2023 Report, Shares Corporate UpdateSeptember 29, 2023 | finance.yahoo.comInMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business UpdateSeptember 15, 2023 | benzinga.comThis Clinical Stage BioPharma Is Seeing Solid Growth In Rare Cannabinoid Demand From The Health And Wellness SectorSeptember 7, 2023 | finance.yahoo.comInMed to Present at H.C. Wainwright 25th Annual Global Investment ConferenceJuly 22, 2023 | au.finance.yahoo.comINM - InMed Pharmaceuticals Inc.See More Headlines Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/19/2024Fiscal Year End6/30/2024Next Earnings (Estimated)10/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INM CUSIPN/A CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,950,000.00 Net Margins-108.02% Pretax Margin-108.00% Return on Equity-53.42% Return on Assets-45.36% Debt Debt-to-Equity Ratio0.07 Current Ratio6.58 Quick Ratio6.59 Sales & Book Value Annual Sales$4.14 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.16Miscellaneous Outstanding Shares6,060,000Free Float5,973,000Market Cap$1.79 million OptionableNot Optionable Beta0.20 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Eric A. Adams B.S. Chem. (Age 61)M.I.B., President, CEO & Director Comp: $347.82kMr. Michael Woudenberg P.Eng. (Age 55)Chief Operating Officer Comp: $287.54kMs. Alexandra Diane-Janet Mancini M.Sc. (Age 71)Senior Vice President of Clinical & Regulatory Affairs Comp: $279.39kDr. Sazzad Hossain M.Sc. (Age 66)Ph.D., Co-Founder Comp: $135.99kMs. N. Netta Jagpal (Age 51)CFO & Corporate Secretary Ms. Sarah Li CPACGA, VP of Accounting & ControllerColin ClancySenior Director of Investor RelationsMr. Jerry P. GriffinVice President of Sales & MarketingDr. Eric Chih-Hsien Hsu (Age 54)Senior Vice President of Preclinical Research & Development Comp: $253.46kDr. Shane A. Johnson Ph.D.Senior VP & GM of BayMedicaMore ExecutivesKey CompetitorsPaxMedicaNASDAQ:PXMD180 Life SciencesNASDAQ:ATNFPanbela TherapeuticsNASDAQ:PBLAAyala PharmaceuticalsNASDAQ:ADXSPainReformNASDAQ:PRFXView All CompetitorsInsidersAndrew HullBought 37,500 shares on 2/21/2024Total: $14,625.00 ($0.39/share)Eric A AdamsBought 41,600 shares on 2/20/2024Total: $14,976.00 ($0.36/share)View All Insider Transactions INM Stock Analysis - Frequently Asked Questions How have INM shares performed in 2024? InMed Pharmaceuticals' stock was trading at $0.4160 on January 1st, 2024. Since then, INM shares have decreased by 29.1% and is now trading at $0.2949. View the best growth stocks for 2024 here. When is InMed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, October 4th 2024. View our INM earnings forecast. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its earnings results on Wednesday, November, 10th. The company reported ($6.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.75) by $2.50. InMed Pharmaceuticals had a negative net margin of 108.02% and a negative trailing twelve-month return on equity of 53.42%. When did InMed Pharmaceuticals' stock split? Shares of InMed Pharmaceuticals reverse split on the morning of Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INM) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
